Alto Neuroscience Inc
ANRO
Company Profile
Business description
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Contact
650 Castro Street
Suite 450
Mountain ViewCA94041
USAT: +1 650 200-0412
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
76
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,690.90 | 53.40 | 0.62% |
| CAC 40 | 7,726.97 | 10.23 | -0.13% |
| DAX 40 | 23,969.55 | 38.88 | 0.16% |
| Dow JONES (US) | 42,305.48 | 35.41 | 0.08% |
| FTSE 100 | 8,785.74 | 11.48 | 0.13% |
| HKSE | 23,512.49 | 354.52 | 1.53% |
| NASDAQ | 19,242.61 | 128.85 | 0.67% |
| Nikkei 225 | 37,446.81 | 23.86 | -0.06% |
| NZX 50 Index | 12,327.23 | 91.66 | -0.74% |
| S&P 500 | 5,935.94 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,466.70 | 52.60 | 0.63% |
| SSE Composite Index | 3,361.98 | 14.49 | 0.43% |